Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million
First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib)
Sovleplenib for ITP accepted for NDA review in China, with Priority Review status an
Read More